Published: September 2025

Last updated: September 2025

From Data to Decisions: Leveraging Statistics to Improve Healthcare Decision-Making

Health economics is an important field not just in the UK but globally. Decision-makers can use it to prioritise resources used in healthcare systems to maximise population health whilst ensuring value for money. Since 1999, the National Institute for Health and Care Excellence (NICE) has been responsible for these decisions in the UK. There is a need to provide these decision-makers with the best possible evidence for new treatments to support well-informed decisions.

The vast majority of health economic modelling is still conducted using Markov models to capture disease progression. However, these models rely on restrictive assumptions that may not accurately capture real-world disease progression. This talk will discuss two examples from a recent publication
where regression modelling was used to improve the health economic model. The first example will cover using a multinomial logistic regression to predict the changes in haemoglobin health states over time in patients with chronic kidney disease. Traditional Markov models assume a fixed disease progression rate which fails to account for patient subgroups and time-varying rates. Regression models enable dynamic transitions based on patient characteristics like age, sex, and baseline haemoglobin levels. This leads to better modelling of disease progression and subsequent decision-making.

The second example will cover using a generalised linear mixed model (GLMM) to estimate drug doses for each haemoglobin health state whilst adjusting for subgroup characteristics. This allows for a more granular approach to cost-effectiveness analysis. Unlike Markov models, which often require simplifying assumptions to capture drug doses, a GLMM better reflects the uncertainty in the target-population.

As real-world evidence and individual patient data (IPD) become more accessible, alongside increasing computational power, statisticians must apply and share advanced modelling approaches. By doing so, we can enhance healthcare decision-making, ultimately leading to better policies and improved population health.

You may also be interested in

Peer-reviewed publication

A Disease Progression Model Comparing the Long-Term Mobility and Respiratory Outcomes of Adults with Late-Onset Pompe Disease Receiving Cipaglucosidase Alfa Plus Miglustat versus Alglucosidase Alfa

YHEC authors: Amy Dymond, Will Green
Publication date: July 2026
Journal: Journal of Comparative Effectiveness Research

Abstract

AIM: Late-onset Pompe disease (LOPD) is a rare lysosomal disease primarily impacting muscle strength andrespiratory function. LOPD has a substantial burden despite the availability of alglucosidase alfa (alg). Patients often...

Peer-reviewed publication

Addressing Real-World Data Gaps: Estimating the UK Population Cost of Crohn’s Disease and Ulcerative Colitis Using A Flexible Cost-of-Illness Model Informed by the Optimal Patient Journey and IBDUK Patient Survey 2023

YHEC authors: Rachael MacDonald, Nick Hex, Barbara Uzdzinska, Jessica Pocock
Publication date: July 2026
Journal: BMC Health Services Research

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions affecting around 500,000 people in the UK and carries rising prevalence and substantial economic...

Peer-reviewed publication

Next Generation Methods in Health Technology Assessment (HTA): Need, Rigor, and Implementability

YHEC authors: Melissa Pegg
Publication date: July 2026
Journal: International Journal of Technology Assessment in Healthcare

Abstract

The Health Technology Assessment International (HTAi) 2025 annual meeting featured three main plenaries to explore next generation (NextGen) evidence in health technology assessment (HTA). In this commentary we capture the...